Sharma, Ashish http://orcid.org/0000-0002-8550-9791
Kumar, Nilesh http://orcid.org/0000-0002-7439-2081
Parachuri, Nikulaa
Kuppermann, Baruch D.
Bandello, Francesco
Regillo, Carl D.
Boyer, David
Nguyen, Quan Dong
Article History
Received: 9 November 2020
Revised: 12 November 2020
Accepted: 12 November 2020
First Online: 2 February 2021
Compliance with ethical standards
:
: AS: Consultant: for Novartis, Allergan, Bayer and Intas. BDK: Clinical research: Alcon, Alimera, Allegro, Allergan, Apellis, Clearside, Genentech, GSK, Ionis, jCyte, Novartis, Regeneron, ThromboGenics; Consultant: Alimera, Allegro, Allergan, Cell Care, Dose, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics, jCyte, Novartis, Ophthotech, Regeneron, Revana, Theravance Biopharma. FB: Consultant: Allergan, Bayer, Boehringer- Ingelheim, Fidia Sooft, Hofmann La Roche, Novartis, NTC Pharma, Sifi, Thrombogenics, Zeiss. CDR: Consultant: Allergan, Chengdu Kanghong, Genentech/Roche, Novartis, Kodiak, Notal, Merck, Takeda, Adverum, Graybug, Eyepoint; research support: Allergan, Chengdu Kanghong, Genentech/Roche, Novartis, Kodiak, Iveric, Adverum, Regeneron, RegenXBio. DB: Consultant: Genentech, Allergan, Roche, Regeneron, Bayer, Novartis. QDN: Consultant/Scientific Advisory Boards: EyePoint, Genentech, Gilead, Regeneron, Santen. The other authors declare that they have no conflict of interest.